GT Biopharma (NASDAQ:GTBP) Stock Price Down 3.3% – Here’s What Happened

GT Biopharma, Inc. (NASDAQ:GTBP)’s share price was down 3.3% during mid-day trading on Thursday . The stock traded as low as $0.38 and last traded at $0.3895. Approximately 594,684 shares changed hands during mid-day trading, a decline of 21% from the average daily volume of 754,989 shares. The stock had previously closed at $0.4027.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of GT Biopharma in a report on Friday, April 10th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

GT Biopharma Price Performance

The business has a 50 day moving average of $0.41 and a 200 day moving average of $0.58. The company has a market cap of $13.87 million, a PE ratio of -0.06 and a beta of 0.64.

Institutional Trading of GT Biopharma

An institutional investor recently bought a new position in GT Biopharma stock. SeaCrest Wealth Management LLC acquired a new stake in shares of GT Biopharma, Inc. (NASDAQ:GTBP) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 50,000 shares of the company’s stock, valued at approximately $37,000. SeaCrest Wealth Management LLC owned 0.47% of GT Biopharma at the end of the most recent quarter. Hedge funds and other institutional investors own 8.15% of the company’s stock.

GT Biopharma Company Profile

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).